Alentis Therapeutics

Investment area
Venture Investments
Region
Europe
Date of investment
April 2023

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.

Alentis Therapeutics

Investment area
Venture Investments
Region
Europe
Date of investment
April 2023

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.

Alentis Therapeutics

Investment area
Venture Investments
Region
Europe
Date of investment
April 2023

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.